Highlights Syncona Limited

Equities

Real-time Estimate Cboe Europe Other stock markets 06:03:43 18/06/2024 pm IST			5-day change	1st Jan Change
114.1 ^GBX	+0.97%		+6.58%	-7.24%

17/06	Syncona’s Freeline, SwanBio Combine to Form Spur Therapeutics	MT
17/06	Syncona to invest GBP40 million into newly created Spur Therapeutics	AN

Syncona’s Freeline, SwanBio Combine to Form Spur Therapeutics	17/06	MT
Syncona to invest GBP40 million into newly created Spur Therapeutics	17/06	AN
Syncona notes Autolus's first quarter loss widens amid higher costs	17/05	AN
Syncona's Freeline gets positive results for Gaucher disease	09/05	AN
Syncona agrees to sell stake in investee company for GBP7.4 million	11/04	AN
Syncona to Sell Stake in Portfolio Company to Century Therapeutics	11/04	MT
Syncona notes investee Achilles's annual loss narrows	04/04	AN
Syncona portfolio company Autolus posts widened loss for 2023	14/03	AN
Syncona’s Takeover of Freeline Therapeutics Becomes Effective	20/02	MT
Freeline shareholders approve Syncona acquisition	12/02	AN
Freeline Therapeutics' Shareholders Approve Acquisition by Syncona	12/02	MT
Syncona portfolio strengthens in third quarter thanks to Autolus	08/02	AN
Tranche Update on Syncona Limited's Equity Buyback Plan announced on September 29, 2023.	08/02	CI
Syncona notes FDA acceptance of Autolus's BLA for obe-cel	22/01	AN
Syncona says Freeline trial for Gaucher disease treatment positive	19/01	AN
Syncona agrees to buyout deal with Freeline Therapeutics	22/11	AN
Syncona to Take Over Freeline Therapeutics	22/11	MT
Freeline Therapeutics to be Acquired by Syncona for $28.3 Million	22/11	MT
Syncona reports declining asset value as investment head steps down	16/11	AN
Syncona Swings to Fiscal H1 Loss; Invest Income Falls	16/11	MT

No results for this search